The Korea Herald

Articles by Lim Jeong-yeo

LATEST NEWS

Today Industry

Merck Korea gives $29,000 to Ansan multicultural children care center

Merck Korea has donated 25,000 euros ($29,000) to an Ansan, Gyeonggi Province, multicultural children care center, the company said Thursday. The fund will be used, among other things, for a Korean-...

Samsung Biologics to develop Kanaph Therapeutics' retinal disease treatment

Samsung Biologics will contract develop Kanaph Therapeutics’ retinal disease treatment, the company announced Thursday. Kanaph’s KNP-301 is a C3bg Inhibitor-VEGF binder novel drug candidate that tre...

Today
Industry
Daewoong, Medytox clash over ITC’s review of determination

Daewoong Pharmaceuticals and Medytox on Tuesday gave contrasting interpretations of the US International Trade Commission‘s announcement to review parts of the final initial determination. The USITC...

September 22, 2020
Industry
Samsung Biologics seizes over $330m deal with AstraZeneca

Samsung Biologics signed to contract manufacture AstraZeneca‘s biologics drug for its global distribution, the company said Tuesday. The size of the contract is $330,840,300, open to grow to $529,59...

September 22, 2020
Industry
First patient administered with COVID-19 plasma treatment in Korea

GC Pharma, a blood plasma-derived medicine company, said Monday that it has administered its COVID-19 plasma treatment GC5131A to the first domestic patient for a phase 2 clinical trial. In Korea, p...

September 21, 2020
Industry
KT suggests founding intl epidemic management working group

KT CEO Ku Hyeon-mo is pushing for the formation of a new global body to address pandemic preparedness utilizing information and communications technology, the South Korean mobile carrier said Sunday....

September 20, 2020
Industry
Samsung Biologics signs CDO deal with Panolos Bioscience

Samsung Biologics signed to contract develop Panolos Bioscience‘s novel anti-cancer drug candidate PB101, the company announced Thursday. Per contract, Samsung Biologics will be responsible for all ...

September 17, 2020
Industry
Samsung Display touts OLED with tightest folds

Samsung Display’s 1.4R OLED offers the highest level of foldability in the industry. (Samsung Display) Samsung Display said Wednesday that its latest organic light-emitting diode displays can fold w...

September 16, 2020
Industry
[Newsmaker] Celltrion on path to break W1tr in operating profit

Celltrion Group is expected to become the first Korean biologics drug company with an operating profit of over 1 trillion won ($850 million), financial data aggregator FnGuide projected Tuesday. T...

September 16, 2020
Industry
[News Focus] Firms look overseas for COVID-19 drug trials

In another case, Celltrion’s existing, already commercially approved biosimilar drug Remsima (infliximab) is being tested in the UK by Oxford University researchers for its ability to suppress what d...

September 15, 2020
Industry
LIG Nex1, Good Will Store share hope through COVID-19

LIG Nex1, an aerospace and defense company, donated some 1,000 everyday essential items to a Good Will Store in Daejeon, in hopes of softening the blow of the COVID-19 pandemic for disabled people. ...

September 13, 2020
Industry
[Weekender] No more high-status vs. low-status jobs?

Encouraging diversity Will such changes in our perceptions of jobs diminish the need for nearly two decades of schooling? Not quite, says Lee Bohm, a social critic of the education system in Korea....

September 12, 2020
Industry
Missing in delivery: Korea counts social media purchases gone wrong

An increasing number of consumers who purchased clothes through social media are reporting complaints of unshipped products and merchants suddenly vanishing altogether. According to Korea Consumer A...

September 11, 2020
Industry
[Newsmaker] Celltrion confirms phase 1 trial safety of COVID-19 antibody drug

Celltrion said Friday that it had confirmed the safety of COVID-19 antibody drug CT-P59 in healthy people through a domestic phase 1 trial involving 32 people. Once another clinical phase 1 trial ta...

September 11, 2020
Industry
SK Biopharmaceuticals plans phase 3 trials of cenobamate in Asia

SK Biopharmaceuticals is on track to conduct phase 3 clinical trials of its novel epilepsy treatment cenobamate in Korea, China and Japan. The company announced Thursday that its phase 3 clinical tr...

September 10, 2020
Industry

The Korea Herald by Herald Corporation

Address : Huam-ro 4-gil 10, Yongsan-gu,Seoul, Korea
Online newspaper registration No : Seoul 아03711
Date of registration : 2015.04.28
Publisher. Editor : Kwon Chung-won
Juvenile Protection Manager : Yang Sung-jin
Tel : 02.727.0114